Goldman Sachs Group Inc Jounce Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.9 - $1.85 $75,441 - $155,074	-83,824 Reduced 66.14%	42,922 $79,000
Q1 2023 May 11, 2023	SELL	$0.9 - $1.85 $75,441 - $155,074	-83,824 Reduced 66.14%	42,922 $79,000
Q4 2022 May 14, 2024	SELL	$0.64 - $1.99 $22,254 - $69,198	-34,773 Reduced 21.53%	126,746 $140,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $22,254 - $69,198	-34,773 Reduced 21.53%	126,746 $140,000
Q3 2022 May 14, 2024	SELL	$2.73 - $4.92 $117,701 - $212,120	-43,114 Reduced 21.07%	161,519 $378,000
Q3 2022 Nov 10, 2022	SELL	$2.73 - $4.92 $117,701 - $212,120	-43,114 Reduced 21.07%	161,519 $0
Q2 2022 May 14, 2024	BUY	$2.8 - $7.67 $572,972 - $1.57 Million	204,633 New	204,633 $620,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $524,392 - $1.44 Million	-187,283 Reduced 47.79%	204,633 $620,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $1.97 Million - $2.81 Million	-328,529 Reduced 45.6%	391,916 $2.66 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $330,750 - $448,443	46,519 Added 6.9%	720,445 $6.02 Million
Q3 2021 Nov 10, 2021	BUY	$5.04 - $8.73 $3.4 Million - $5.88 Million	673,926 New	673,926 $5.01 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.